Skip to main content
SpringerLink
Log in

Liver Disease and Anticancer Drug Treatment

  • Chapter
Drugs and the Liver: High Risk Patients and Transplantation

Part of the book series: Medical Science Symposia Series ((MSSS,volume 4))

  • 51 Accesses

Abstract

Anticancer drugs probably have the smallest therapeutic index of any drugs. They are one of the few classes of therapeutic agents that are routinely given to patients at doses producing moderate to severe toxicity. Significant patient toxicity is closely associated with the use of all the effective anticancer drugs (1). There is good evidence that higher doses of anticancer drugs offer a greater likelihood of therapeutic response and in order to achieve the maximum therapeutic activity significant patient morbidity has to be tolerated (2–4). An unfortunate sequela is that because of human variability there will be some patients who experience severe, even life threatening, toxic responses to the standard doses of anticancer drugs. Clinicians are well used to titrating the dose of anticancer drugs. However, an understanding of the causes of human variability in toxic response to anticancer drugs can go a long way to avoiding unnecessary toxicity and can improve the quality of life of cancer patients. A significant cause of pharmacokinetic variability in the response to anticancer drugs, and one that forms the basis for dose reduction of some anticancer drugs, is liver dysfunction (5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Powis G. (1991): The Toxicity of Anticancer Drugs. Pergamon Press, New York.

    Google Scholar 

  2. DeVita V.T. (1989): In: Cancer Principles and Practice of Oncology, edited by V.T. DeVita, S. Hellman, and S.A. Rosenberg pp. 276–300. Lippincott, Philadelphia.

    Google Scholar 

  3. Frei E., Canellas G.P. (1980): Am. J. Med., 69: 585–594.

    Article  PubMed  Google Scholar 

  4. Gehan E.A. (1984): Cancer, 54: 1204–1207.

    Article  PubMed  CAS  Google Scholar 

  5. Powis G. (1983): Pharmacokinetics of anticancer agents in humans. Elsevier, Amsterdam.

    Google Scholar 

  6. McDonald G.B., Tirumali N. (1984): West. J. Med., 140: 250–259.

    PubMed  CAS  Google Scholar 

  7. Zimmerman H.J. (1988): Prog. Liver Dis., 8: 621–642.

    Google Scholar 

  8. Ozarda A., Pickren J. (1962): J. Nucl. Med., 3: 149–152.

    Google Scholar 

  9. Mendelsohn M.L., Bodansky 0. (1952): Cancer, 5: 1–7.

    Article  PubMed  CAS  Google Scholar 

  10. Schaefer J., Schiff L. (1965): Gastroenterology, 49: 360–363.

    PubMed  CAS  Google Scholar 

  11. Hepner G.W., Uhlin S.R., Lipton A., Harvey H.A., Rohrer G.V. (1976): J. Am. Med. Assoc., 236: 1587–1590.

    Article  CAS  Google Scholar 

  12. Higuchi Z., Nakamura T., Uchino H. (1980): Cancer, 45: 541–544.

    Article  PubMed  CAS  Google Scholar 

  13. Pelkonen O., Karki N.T., Larmi T.K.I. (1973): Chir. Gastroenterol., 7: 436–443.

    Google Scholar 

  14. Kato R. (1963): Experientia, 19: 31–32.

    Article  PubMed  CAS  Google Scholar 

  15. Bartosek I., Donelli M.G., Guaitani A., Colombo T., Russo R., Garattini S. (1975): Biochem. Pharmacol., 24: 289–291.

    Article  PubMed  CAS  Google Scholar 

  16. Kato R., Takanaka A., Takahashi H., Onoda K. (1968): Jpn. J. Pharmacol., 18: 224–244.

    Article  PubMed  CAS  Google Scholar 

  17. Rosso R., Dolfini E., Donelli M.G. (1968): Eur. J. Cancer, 4: 133–135.

    PubMed  CAS  Google Scholar 

  18. Rosso R., Donelli M.G., Franchi G., Garattini S. (1971): Eur. J. Cancer, 7: 565–577.

    PubMed  CAS  Google Scholar 

  19. Tschanz C., Hignite C.E., Huffman D.A., Azarnoff D.L. (1977): Cancer Res., 37: 3881–3886.

    PubMed  CAS  Google Scholar 

  20. Powis G., Harris R.N., Basseches P.J., Santone K.S. (1986): Cancer Chemother. Pharmacol., 16: 43–49.

    Article  PubMed  CAS  Google Scholar 

  21. Friedman R.B., Anderson R.E., Entine S.M., Hirshberg S.B. (1980): Clin. Chem., 26 (Suppl.): 1–475.

    Google Scholar 

  22. Dorr R.T., Fritz W.L. (1980): In: Handbook of Cancer Chemotherapy, pp. 685–691. Elsevier, New York.

    Google Scholar 

  23. Holland J.F., Scharlau C., Gailani S., Krant M.J., Olson K.B., Horton J., Shnider B.1., Lynch J.J., Owens A., Carbone P.P., Grob D., Miller S.P., Hall T.C. (1973): Cancer Res., 33: 1258–1264.

    PubMed  CAS  Google Scholar 

  24. Sandler S.G., Tobin W., Henderson E.S. (1969): Neurology, 19: 367–374.

    Article  PubMed  CAS  Google Scholar 

  25. Watkins S.M., Griffin J.P. (1978): Br. Med. J., 1: 610–612.

    Article  PubMed  CAS  Google Scholar 

  26. Jackson D.V., Castle M.C., Bender R.A. (1978): Clin. Pharmacol. Ther., 24: 101–107.

    PubMed  Google Scholar 

  27. Bender R.A., Zwelling L.A., Doroshow J.H., Locker G.Y., Hande K.R., Murinson D.S., Cohen M., Myers C.E., Chabner B.A. (1978): Drugs, 16: 46–87.

    Article  PubMed  CAS  Google Scholar 

  28. Mueller J.M. Flaherty M.J. (1978): South. Med. J. 71: 1301–1311.

    Article  Google Scholar 

  29. Edmonson J. A., Peters R.L. (1982): In: Diseases of the Liver, edited by L. Schiff and E.R. Schiff pp. 1101–1140.

    Google Scholar 

  30. Glode L.M., Israel M., Pegg W.J., Wilkinson P.M. (1977): Br. J. Clin. Pharmacol., 4: 639.

    Article  Google Scholar 

  31. Riggs C.E., Benjamin R.S., Serpick A.A., Bachur N.R. (1977): Clin. Pharmacol. Ther., 22: 234–241.

    PubMed  Google Scholar 

  32. Benjamin R.S., Wiernik P.H., Bachur N.R. (1974): Cancer, 33: 19–27.

    Article  PubMed  CAS  Google Scholar 

  33. Bachur N.R., Riggs C.E., Green M.R., Langore M.R., Van Vurakis J.J., Levine L. (1977): Clin. Pharmacol. Ther., 21: 70–77.

    PubMed  CAS  Google Scholar 

  34. Benjamin R.S., Loo T.L., Friedman J., Ho D.H., Rodriquez V., Gottlieb J.A., Freireich E.J. (1975): Pharmacologist, 17: 265.

    Google Scholar 

  35. Gisselbrecht C., Likiec F., Marty M., Mignot L., Belpomme D., Najean Y., Boiron M. (1980): Cancer Chemother. Pharmacol., 5 (Suppl.): 20.

    Google Scholar 

  36. Doroshow J., Chan K. (1982): Proc. Am. Assoc. Clin. Oncol., 1: 11.

    Google Scholar 

Download references

Authors
  1. G. Powis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Surgical Researches and Transplantation, Ospedale Maggiore Policlinico di Milano, University of Milan, Milan, Italy

    D. Galmarini  & L. R. Fassati  & 

  2. Institute of Pharmacological Sciences, University of Milan, Milan, Italy

    R. Paoletti

  3. Royal Free Hospital School of Medicine, University of London, London, UK

    S. Sherlock

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Powis, G. (1993). Liver Disease and Anticancer Drug Treatment. In: Galmarini, D., Fassati, L.R., Paoletti, R., Sherlock, S. (eds) Drugs and the Liver: High Risk Patients and Transplantation. Medical Science Symposia Series, vol 4. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1994-8_16

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-1994-8_16

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-5748-6

  • Online ISBN: 978-94-011-1994-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation